

C.BIRD- Augment the Human T Cell Activation in Standard 96-well Plates Using the C.BIRD Microbioreactor

Nora Yu, MS, Charles Tsai, PhD
CYTENA Bioprocess Solutions, Taipei City, Taiwan



Abstract

T cell-based immunotherapies are popular cancer treatments, and require procuring a large number of T cells. T cells that are isolated from the patient need to be optimally activated and expanded in vitro, then re-infused back to the patient for fighting cancer cells. This study sought to improve

the activation level of human T cells in 96-well plates by introducing a novel C.BIRD™ cell culture method. Study results showed that the C.BIRD cell culture method enhanced the activation level of human T cells, but did not cause unwanted activation. This study demonstrates a great potential to improve T cell-based immunotherapies studies by accelerating the process development workflow.

Introduction

Adoptive cell therapy (also known as cellular immunotherapy) is a cancer treatment that uses a patient's immune cells to eliminate cancer. T cell-based therapy is the mainstream immunotherapy today. There are different types of T cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, and chimeric antigen receptor (CAR) T cell therapy. All of these T cell therapies require a high number of T cells to be re-infused into a patient. Therefore, expanding the number of isolated T cells, with or without genetic engineering, is the cornerstone of T cell therapies. Accordingly, T cell activation is the critical step in researching or manufacturing T cell-based therapies, which involves gene editing and non-clonal expansion. Efficient activation of T cells may accelerate the workflow of T cell-based cell therapies and reduce development time.

Previous data have shown that the C.BIRD microbioreactor can improve the growth of Jurkat cells, a human T cell line, through continuous mixing mode. To reinforce the T cell expansion workflow, the T cell activation level in the C.BIRD culture system was tested. We activated the Jurkat cell line in a C.BIRD 96-well culture system and found that the gentle mixing mode can improve T cell activation level compared to standard static culture. Results suggest an ideal activation mode or human T cells and a more effective way of process development for T cell-based cell therapy.

Materials and methods

The Jurkat cell line, an immortalized human T lymphocyte, was the model used in this study. Jurkat cells were cultured in RPMI 1640 (Corning #10-040-CV) supplied with 10% FBS (Gibco #10437028), 2 mM L-glutamine (Corning #25-005-CI), 10 mM HEPES (Gibco #15630080), 1 mM sodium pyruvate (Gibco #11360070), 2,500 mg/L D-(+)-glucose (Merck #G7021) and 1x Penicillin-Streptomycin solution (Corning #30-002-CI). Standard 96-well cell culture plates (Eppendorf #0030 730.011) were used for this experiment. Comparison studies were performed with cells cultivated in standard static culture and C.BIRD suspension culture in a 5% CO₂ humidified atmosphere at 37°C.

The cell density of both the static and C.BIRD groups was 5×10^4 cells per well in 150 μ L medium. The Jurkat cells were activated with Dynabeads™ Human T-Activator CD3/CD28 (ThermoFisher scientific #111.61D). The tested ratio of Dynabeads to Jurkat cells were 0-to-1, 1-to-1, 3- to-1, and 5-to1. The C.BIRD mixing rate was 40 s/cycle continuous mixing mode. The IL-2 expression levels were determined using ELISA MAX™ Deluxe Set Human IL-2 ELISA kit (#431804, Biolegend). Data were analyzed by an unpaired t test. Significance of *P* value is listed as the following: 0.05 (ns), <0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****).





Figure 1. Diagram of experiment design

Results and discussion

The human T cell activation experiment was designed as shown in **Figure 1**. The human T cells formed clusters and started to proliferate during activation. We observed the morphology of Jurkat cells after Dynabeads Human T-Activator CD3/CD28 treatment for 24 hours (**Figure 2A**). Results show the Jurkat cells formed larger cell clusters as the ratio of CD3/CD28 Dynabeads to Jurkat cells increased. And cell clusters in the C.BIRD culture were larger than in static culture.

The other indicator of T-cell activation is the specific cytokines production, such as interleukin 2 (IL-2). The expression of secreted IL-2 from CD3/CD28

Dynabeads treated Jurkat cells (**Figure 2B**) was measured. No significant difference was observed in IL-2 expression level between static culture and C.BIRD culture without Dynabeads stimulation ($P = 0.2943$), suggesting that C.BIRD mixing culture does not affect T-cell activation without stimulation. The expression of IL-2 of C.BIRD cultures was significantly higher than in static cultures in all groups of CD3/CD28 Dynabeads-treated Jurkat cells. The P value of IL-2 expressions in CD3/CD28 Dynabeads-to-Jurkat cells co-culture ratio of 1-to-1, 3-to-1, and 5-to-1 were 0.0078, 0.0033, and 0.0002, respectively. These results demonstrated that the C.BIRD culture method could improve the T cells activation.



Conclusion and future direction

T cell activation is an important procedure in the development or manufacturing process of T cell-based cell therapies. This study showed that the

C.BIRD culture method augmented the activation level of the human T cell line in a 96-well culture scale. This feature can integrate with another C.BIRD function, improving human T cells growth. These features can help researchers shorten the timeline for process development of T cell-based cell therapies by using the C.BIRD culture method.

References

1. Majedi FS, Hasani-Sadrabadi MM, Thauland TJ, et al. Augmentation of T-Cell Activation by Oscillatory Forces and Engineered Antigen-Presenting Cells. *Nano Letters*. 2019 19 (10), 6945-6954. DOI: [10.1021/acs.nanolett.9b02252](https://doi.org/10.1021/acs.nanolett.9b02252)
2. Poltorak MP, Graef P, Tschulik C, et al. Expamers: a new technology to control T cell activation. *Scientific Reports*. 2020; 10, 17832. DOI:[10.1038/s41598-020-74595-8](https://doi.org/10.1038/s41598-020-74595-8)



©2022 BICO AB. All rights reserved. Duplication and/or reproduction of all or any portion of this document without the express written consent of BICO is strictly forbidden. Nothing contained herein shall constitute any warranty, express or implied, as to the performance of any products described herein. Any and all warranties applicable to any products are set forth in the applicable terms and conditions of sale accompanying the purchase of such product. BICO provides no warranty and hereby disclaims any and all warranties as to the use of any third-party products or protocols described herein. The use of products described herein is subject to certain restrictions as set forth in the applicable terms and conditions of sale accompanying the purchase of such product. BICO may refer to the products or services offered by other companies by their brand name or company name solely for clarity and does not claim any rights to those third-party marks or names. BICO products may be covered by one or more patents. The use of products described herein is subject to BICO's terms and conditions of sale and such other terms that have been agreed to in writing between BICO and user. All products and services described herein are intended FOR RESEARCH USE ONLY and NOT FOR USE IN DIAGNOSTIC PROCEDURES.

The use of BICO products in practicing the methods set forth herein has not been validated by BICO, and such nonvalidated use is NOT COVERED BY BICO'S STANDARD WARRANTY, AND BICO HEREBY DISCLAIMS ANY AND ALL WARRANTIES FOR SUCH USE. Nothing in this document should be construed as altering, waiving or amending in any manner BICO's terms and conditions of sale for the instruments, consumables or software mentioned, including without limitation such terms and conditions relating to certain use restrictions, limited license, warranty and limitation of liability, and nothing in this document shall be deemed to be Documentation, as that term is set forth in such terms and conditions of sale. Nothing in this document shall be construed as any representation by BICO that it currently or will at any time in the future offer or in any way support any application set forth herein.

CBSAPP07